Sarpogrelate
As of the edition of 20 October 2026, Sarpogrelate is a small molecule: in active development; acts on HTR2A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2009
- Kind
- Small molecule
- Registered trials
- 21, 0 stopped early
- Disease areas
- Heart and blood vessels; Nervous system; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HTR2A | 5-hydroxytryptamine receptor 2A | P28223 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 1 | 0 |
| Phase 1 | 8 | 7 | 0 | 0 |
| Phase 3 | 3 | 3 | 0 | 0 |
| Phase 4 | 7 | 4 | 0 | 0 |
| All trials | 21 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Tanabe Pharma | Lead sponsor of trials | 2001 to now |
| Alvogen | Lead sponsor of trials | 2011 to now |
| United Pharm | Lead sponsor of trials | 2011 to now |
| Daewoong | Lead sponsor of trials | 2018 to now |
| Yuhan | Lead sponsor of trials | 2018 to now |